Exelixis, Inc. with ticker code (EXEL) now have 20 market analysts covering the stock. The analyst consensus now points to a rating of ‘buy’. The target price High/Low ranges between $32.00 and $17.00 calculating the mean target share price we have $26.55. (at the time of writing). Now with the previous closing price of $22.05 this would imply there is now a potential upside of 20.4%. The 50 day MA is $21.74 and the 200 moving average now moves to $22.05. The total market capitalization for the company now stands at 6.57B. The current share price for the company is: $22.55 USD
The potential market cap would be $7,909,199,120 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 34.69, revenue per share of $5.91 and a 4.3% return on assets.
Exelixis, Inc. is an oncology company. The Company is engaged in developing medicines and combination regimens at the forefront of cancer care. It has four products, including its flagship molecule, cabozantinib, which is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET. Cabozantinib is approved as CABOMETYX tablets used for advanced renal cell carcinoma (RCC), both alone and in combination with Bristol-Myers Squibb Company’s (BMS) OPDIVO (nivolumab), for hepatocellular carcinoma (HCC) and for radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC). Cabozantinib is also approved as COMETRIQ capsules for metastatic medullary thyroid cancer (MTC). Its other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor (MR) approved the treatment of hypertension.
